Head-to-head
MOTS-c vs NAD+
A field-by-field comparison of MOTS-c and NAD+ drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — metabolic and longevity — so this page focuses on what each one actually does rather than which is "better".
MOTS-c vs NAD+ at a glance
| Attribute | MOTS-c | NAD+ |
|---|---|---|
| Category | Metabolic | Longevity |
| Evidence grade | Emerging | Emerging |
| Also known as | Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide | Nicotinamide adenine dinucleotide |
| Chain | 16 amino acid mitochondrial-derived peptide | Coenzyme (dinucleotide, not a peptide) |
| Mechanism | Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. | Serves as an electron carrier in redox reactions and as the required substrate for sirtuins and PARP enzymes, which govern DNA repair and mitochondrial biogenesis. |
| Reported benefits | Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction | Reported energy and mental-clarity improvements · Supports sirtuin-mediated DNA repair pathways · Used adjunctively in recovery clinics |
| Reported side effects | Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals | Flushing, chest tightness and nausea during rapid infusion · Injection-site pain · Headache |
| Half-life | Estimated minutes to a few hours | Very short in circulation |
| Administration | Subcutaneous injection; oral capsules are marketed but less validated | IV infusion, subcutaneous injection or nasal spray |
| Dosing overview | Commonly cited at 5–10 mg daily, often for 4–12 week cycles | IV 250–750 mg per session; subcutaneous 50–100 mg several times weekly |
| Storage | Lyophilised powder refrigerated; reconstituted vials 2–8 °C and used within ~30 days | Refrigerated, light-protected |
| Legal status | Research chemical; not approved as a drug. | Compounded and sold in clinics; not an approved drug for ageing. |
Key differences between MOTS-c and NAD+
Different categories, different goals
MOTS-c is indexed under metabolic, while NAD+ sits under longevity. They are not substitutes for one another: MOTS-c is described as "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects." and NAD+ as "A central metabolic coenzyme injected or infused in longevity clinics; declining NAD+ is a hallmark of biological ageing."
Mechanism of action
MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. NAD+: Serves as an electron carrier in redox reactions and as the required substrate for sirtuins and PARP enzymes, which govern DNA repair and mitochondrial biogenesis.
Half-life and dosing frequency
MOTS-c is listed at estimated minutes to a few hours; NAD+ at very short in circulation. That difference is what drives the reported schedules: Commonly cited at 5–10 mg daily, often for 4–12 week cycles versus IV 250–750 mg per session; subcutaneous 50–100 mg several times weekly
Route of administration
MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated. NAD+ is administered by iv infusion, subcutaneous injection or nasal spray.
Legal and regulatory status differs
MOTS-c: Research chemical; not approved as a drug. NAD+: Compounded and sold in clinics; not an approved drug for ageing. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days. NAD+ is stored refrigerated, light-protected.
What MOTS-c and NAD+ have in common
- Evidence grade: both listed as Emerging
Each compound in brief
MOTS-c
Metabolic · Emerging evidence
A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.
Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection
NAD+
Longevity · Emerging evidence
A central metabolic coenzyme injected or infused in longevity clinics; declining NAD+ is a hallmark of biological ageing.
Considerations: Precursors (NR, NMN) are cheaper and orally available with better human data · Infusions must be run slowly or they are extremely uncomfortable · Benefit in healthy young adults is unclear
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.